微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 0.32% | -89.26% | 110.81% | 37/52 | 3.55% | 澳洋健康 | 34.16% | 行业排名> |
| 2024-06-30 | -2.96% | -6020% | 21.9% | 45/52 | 2.24% | 澳洋健康 | 30.56% | 行业排名> |
| 2024-03-31 | -3.79% | -60.59% | -162.85% | 49/52 | 1.22% | 澳洋健康 | 28.14% | 行业排名> |
| 2023-12-31 | 6.03% | 182.26% | 102.35% | 22/52 | 3.83% | 澳洋健康 | 39.54% | 行业排名> |
| 2023-09-30 | 2.98% | 159.96% | 5860% | 34/52 | 6.78% | 澳洋健康 | 61.84% | 行业排名> |
| 2023-06-30 | 0.05% | 100.55% | 102.12% | 39/52 | 1.93% | 澳洋健康 | 48.34% | 行业排名> |
| 2023-03-31 | -2.36% | 57.25% | 67.8% | 47/52 | 2.55% | 澳洋健康 | 58.19% | 行业排名> |
| 2022-12-31 | -7.33% | -905.49% | -47.48% | 43/52 | -0.52% | *ST宜康 | 75.53% | 行业排名> |
| 2022-09-30 | -4.97% | -62.42% | 44.96% | 45/52 | 11.21% | 博腾股份 | 39.77% | 行业排名> |
| 2022-06-30 | -9.03% | -86.19% | -63.59% | 47/52 | 5.46% | 睿智医药 | 41.16% | 行业排名> |
| 2022-03-31 | -5.52% | -0.73% | -706.59% | 42/52 | 3.09% | 澳洋健康 | 51.68% | 行业排名> |
| 2021-12-31 | 0.91% | 111.61% | 129.74% | 39/52 | -6.4% | 澳洋健康 | 40.93% | 行业排名> |
| 2021-09-30 | -3.06% | 58.65% | 36.91% | 36/52 | 2.38% | 金域医学 | 43.58% | 行业排名> |
| 2021-06-30 | -4.85% | 57.64% | 11.5% | 45/52 | 2.32% | 金域医学 | 35.41% | 行业排名> |
| 2021-03-31 | -5.48% | 33.98% | 30.1% | 33/52 | 1.85% | 阳光诺和 | 26.2% | 行业排名> |
| 2020-12-31 | -7.84% | 43.35% | -5.95% | 45/52 | 10.94% | 金域医学 | 13.23% | 行业排名> |
| 2020-09-30 | -7.4% | -224.16% | 35.37% | 30/52 | 7.83% | 万邦医药 | 52.05% | 行业排名> |
| 2020-06-30 | -11.45% | -440.09% | -37.95% | 38/52 | 2.51% | 华大基因 | 48.52% | 行业排名> |
| 2020-03-31 | -8.3% | -356.04% | 40.03% | 29/52 | -0.22% | 华大基因 | 31.24% | 行业排名> |
| 2019-12-31 | -13.84% | -228.51% | -332.21% | 44/52 | 64.11% | 阳光诺和 | 13.99% | 行业排名> |
| 2019-09-30 | 5.96% | -10.11% | 381.13% | 17/52 | 10.46% | 南华生物 | 2848.07% | 行业排名> |
| 2019-06-30 | -2.12% | -237.66% | -16.48% | 31/52 | 5.56% | 南华生物 | 98.98% | 行业排名> |
| 2019-03-31 | -1.82% | -6.43% | -116.9% | 29/52 | 3.44% | 南华生物 | 82.46% | 行业排名> |
| 2018-12-31 | 10.77% | -14.52% | 62.44% | 22/52 | -0.5% | 南华生物 | 48.41% | 行业排名> |
| 2018-09-30 | 6.63% | 52.06% | 330.52% | 16/52 | 2.84% | 万邦医药 | 106.72% | 行业排名> |
| 2018-06-30 | 1.54% | 220.83% | 190.06% | 25/52 | 1.7% | 国际医学 | 46.66% | 行业排名> |
| 2018-03-31 | -1.71% | 22.27% | -113.57% | 27/52 | 0.49% | 普蕊斯 | 22.99% | 行业排名> |
| 2017-12-31 | 12.6% | 29.36% | 188.99% | 13/52 | 2.03% | 通策医疗 | 6.02% | 行业排名> |
| 2017-09-30 | 4.36% | 41.1% | 808.33% | 20/52 | 8.61% | 普蕊斯 | 58.68% | 行业排名> |
| 2017-06-30 | 0.48% | 148.48% | 121.82% | 27/52 | 58.64% | 爱尔眼科 | 20.87% | 行业排名> |
| 2017-03-31 | -2.2% | 48.96% | -122.59% | 22/52 | -5.59% | 南华生物 | 1666.98% | 行业排名> |
| 2016-12-31 | 9.74% | 13.92% | 215.21% | 18/52 | 19.64% | 爱尔眼科 | 5.19% | 行业排名> |
| 2016-09-30 | 3.09% | -4.92% | 412.12% | 15/52 | 5.93% | 南华生物 | 383.03% | 行业排名> |
| 2016-06-30 | -0.99% | -150.51% | 77.03% | 21/52 | 3.33% | *ST宜康 | 36.84% | 行业排名> |
| 2016-03-31 | -4.31% | 25.82% | -150.41% | 19/52 | 1.51% | 药石科技 | 24.53% | 行业排名> |
| 2015-12-31 | 8.55% | -37.45% | 163.08% | 19/52 | 22.23% | 南华生物 | 55.01% | 行业排名> |
| 2015-09-30 | 3.25% | -69.74% | 65.82% | 14/52 | 5.27% | *ST宜康 | 36.74% | 行业排名> |
| 2015-06-30 | 1.96% | -37.58% | 133.73% | 13/52 | -30.81% | 南华生物 | 24.73% | 行业排名> |
| 2015-03-31 | -5.81% | -605.22% | -142.5% | 18/52 | -5.77% | 南华生物 | 400.84% | 行业排名> |
| 2014-12-31 | 13.67% | 757.21% | 27.28% | 12/52 | -13% | 金域医学 | 22.92% | 行业排名> |
| 2014-09-30 | 10.74% | 17.89% | 242.04% | 7/52 | -106.33% | 迪安诊断 | 11.5% | 行业排名> |
| 2014-06-30 | 3.14% | 40.18% | 173.04% | 9/52 | -89.54% | 退市海医 | 6.75% | 行业排名> |
| 2014-03-31 | 1.15% | -9.45% | 155.29% | 10/52 | -7.99% | 国际医学 | 5.94% | 行业排名> |